Reuters logo
a month ago
BRIEF-Abeona Therapeutics receives FDA orphan drug designation for ABO-201 juvenile Batten disease gene therapy program
June 29, 2017 / 12:20 PM / a month ago

BRIEF-Abeona Therapeutics receives FDA orphan drug designation for ABO-201 juvenile Batten disease gene therapy program

1 Min Read

June 29 (Reuters) - Abeona Therapeutics Inc

* Abeona Therapeutics receives FDA orphan drug designation for ABO-201 juvenile Batten disease gene therapy program

* Abeona Therapeutics Inc - Look forward to initiating human clinical trials later this year for ABO-201 program​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below